A new experimental monoclonal antibody developed by AstraZeneca is being watched as a possible contender to shake up the market for lupus treatments—a neglected disease space—by offering a more targeted approach to treating lupus.
Over the past 60 years there has been only one new FDA-approved treatment for the inflammatory disease: The FDA granted marketing approval to GlaxoSmithKline’s Benlysta in 2011.
{iframe}http://www.mmm-online.com/pipeline/drugmakers-eye-market-potential-for-lupus/article/453351/{/iframe}